Dr. Paul Parren has been working in the field of recombinant antibodies for over 25 years. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Dr. Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California, where he worked between 1993 and 2002 on studying the role of human antibodies in protection against viral infections. In 2002, he joined Genmab where he is a member of the senior management team. Dr. Parren serves in the position of Senior Vice President and Scientific Director and he heads the Genmab site in Utrecht, the Netherlands. He leads an international group of about 125 employees responsible for Genmab's Research and Pre-clinical development activities. Dr. Parren was appointed Professor of Translational Cancer Research at the University of Southern Denmark, Odense, Denmark in 2013. Dr. Parren is dedicated to studying antibody biology and immunotherapy and to translate this knowledge into innovative antibody therapeutics and technologies. Currently, his studies focus on antibody structure-function relationships, antibody effector functions, bispecific antibodies, antibody-drug conjugates and antibody drug discovery and development. Specialties: Immunotherapy, (Human) Antibodies, Drug Discovery and Development, Antibody Effector Functions, Mechanisms of Action, Cancer, Infectious Disease, HIV-1/AIDS

Professor of Molecular Immunology @ From January 2015 to Present (10 months) LeidenAdjunct Professor of Translational Cancer Research @ From July 2013 to Present (2 years 4 months) Odense, DenmarkSr Vice President & Scientific Director @ From January 2002 to Present (13 years 10 months) Associate Professor @ From October 1993 to December 2001 (8 years 3 months) Senior Research Associate @ From August 1992 to October 1993 (1 year 3 months) Research Fellow @ From August 1987 to June 1992 (4 years 11 months)

Ph.D., Molecular Immunology @ University of Amsterdam From 1987 to 1992 M.Sc., Molecular Biology & Immunology @ University of Amsterdam From 1981 to 1987 Paul Parren is skilled in: Drug Discovery, Antibodies, Cancer, In Vivo, Clinical Development, Infectious Diseases, Patents, Biotechnology, Immunology, Lifesciences, Biopharmaceuticals, Licensing, Biologics, Vaccines, Monoclonal Antibodies, Protein Chemistry, R&D, Biochemistry, High Throughput..., GCP, Molecular Biology, Drug Development, Bioinformatics, Immunotherapy, Cell, Protein Expression, Technology Transfer, ELISA, Oncology